1113. Deputy Ken O'Flynn asked the Minister for Health the specific clinical, operational, and patient safety criteria used by Children's Health Ireland to determine "organisational readiness" for transfer to the National Children's Hospital; and whether these criteria will be published. [32738/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
27,342 questions match, newest first.
1114. Deputy Ken O'Flynn asked the Minister for Health whether any independent external validation or audit is required before a Go/No-Go decision on the transfer to the National Children's Hospital is confirmed; and if so, to provide details. [32739/26]
1115. Deputy Ken O'Flynn asked the Minister for Health what contingency planning is in place in the event that a Go/No-Go decision is reversed within the 15-day decision window; and the estimated operational and financial impact of such a reversal. [32740/26]
1116. Deputy Ken O'Flynn asked the Minister for Health to provide the exact whole-time equivalent staffing complement currently assigned to the dementia-specific unit at Heather House Community Nursing Unit, broken down by grade, including nursing, healthcare assistants, and all support staff. [32743/26]
1117. Deputy Ken O'Flynn asked the Minister for Health whether a final, formally approved workforce model has been signed off for Heather House Community Nursing Unit; if so, the date of approval; and if not, the reason a unit is reopening in advance of such approval. [32744/26]
1118. Deputy Ken O'Flynn asked the Minister for Health to confirm whether the current staffing levels at the dementia-specific unit at Heather House Community Nursing Unit are fully compliant with HIQA standards for residential care settings; and whether any risks or variances have been identified. [32745/26]
1119. Deputy Ken O'Flynn asked the Minister for Health whether full funding has been formally approved and allocated for the complete staffing complement required to operate the dementia-specific unit at Heather House Community Nursing Unit at full capacity; and if not, the shortfall. [32746/26]
1120. Deputy Ken O'Flynn asked the Minister for Health whether the staffing model originally developed for a 104-bed facility has been revised to reflect the reduction in capacity to approximately 102 beds and the dementia unit reduction from 19 to 17 beds; and to provide the updated model. [32747/26]
1121. Deputy Ken O'Flynn asked the Minister for Health whether any patients in the State currently have access to omaveloxolone, marketed as Skyclarys, for Friedreich’s ataxia through compassionate use, named patient access, hospital-level approval, exceptional funding, or any other interim access mechanism pending a final HSE reimbursement decision; and if she will make a statement on the matter. [32771/26]
1122. Deputy Ken O'Flynn asked the Minister for Health the number of patients in the State known to the HSE or the Department of Health who are clinically eligible for treatment with omaveloxolone, marketed as Skyclarys, for Friedreich’s ataxia; and if this number has informed any budget impact assessment. [32772/26]
1123. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has a target timeline for completing reimbursement decisions in respect of orphan medicines or medicines for progressive rare diseases; and if no such target exists, whether one is under consideration. [32773/26]
1124. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has any escalation process where a reimbursement application concerns a progressive neurological condition in which delay may lead to irreversible deterioration. [32774/26]
1125. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has considered international reimbursement or access decisions in respect of omaveloxolone, marketed as Skyclarys, including decisions in France, Italy, Germany or other comparable European countries, as part of the Irish reimbursement process. [32775/26]
1126. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE has examined the favourable reimbursement opinion issued in France for Skyclarys in Friedreich’s ataxia, and whether such international assessments are considered in Irish rare disease reimbursement decisions. [32776/26]
1127. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE is aware that Italy’s medicines authority approved reimbursement of Skyclarys for Friedreich’s ataxia in December 2025, and whether this decision has been considered in the Irish process. [32777/26]
1128. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has received a commercial proposal from Biogen Idec Ireland Limited in respect of omaveloxolone, marketed as Skyclarys, since 16 April 2026; and if not, what steps the HSE is taking to progress the matter. [32778/26]
1129. Deputy Ken O'Flynn asked the Minister for Health whether any statutory, contractual, policy or administrative time limits apply where a marketing authorisation holder has been invited to submit a commercial proposal for a medicine but has not yet done so. [32779/26]
1130. Deputy Ken O'Flynn asked the Minister for Health whether she will consider introducing a formal interim access pathway for rare disease medicines where a treatment has European marketing authorisation, there is no alternative disease-modifying therapy available, and the reimbursement process remains unresolved. [32780/26]
1131. Deputy Ivana Bacik asked the Minister for Health if she is aware that the HSE is in ownership of a swimming pool facility at Elm Park, Dublin 4; and her plans to ensure that it be preserved to provide additional swimming facilities for the local community. [32789/26]
1132. Deputy Pearse Doherty asked the Minister for Health the reason an internal review has not been commissioned regarding one of two complaints (details supplied) submitted to St. James’s Hospital, Dublin; and if she will make a statement on the matter. [32790/26]
1133. Deputy Barry Heneghan asked the Minister for Health whether her Department has examined the practice of pharmacies charging additional fees for dispensing medications in blister packs where this is clinically required, particularly for older persons with complex medication regimes; whether any guidance or regulation exists governing such charges under the community drug schemes; if consideration is being given …
1134. Deputy Barry Ward asked the Minister for Health the position regarding any research being carried out into the viability of providing treatment for people suffering from Friedrichs ataxia in Ireland; and if she will make a statement on the matter. [32792/26]
1135. Deputy Barry Ward asked the Minister for Health the position regarding any engagement she has had with families or support groups for people suffering from Friedrichs ataxia in Ireland; and if she will make a statement on the matter. [32793/26]
1136. Deputy Barry Ward asked the Minister for Health the position regarding the approval process for skyclarys as a treatment for Friedrichs ataxia; and if she will make a statement on the matter. [32794/26]
1137. Deputy Barry Ward asked the Minister for Health her views on whether the delays in the approval of skyclarys as a treatment for Friedrichs ataxia aligns with the "equitable access" as outlined in the National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [32795/26]